PHARMACOKINETICS, SAFETY, AND TOLERABILITY OF ETRASIMOD (APD334) IN SUBJECTS WITH MILD, MODERATE, OR SEVERE HEPATIC IMPAIRMENT: A SINGLE-DOSE, OPEN-LABEL, PARALLEL-GROUP STUDY

Caroline A. Lee  1     Yong Tang  1     Cassandra Schroeder  1     Jinkun Zhang  1     Thai Nguyen-Cleary  1     Susan Mullin  1     Michael Ma  1     Naomi Lyon  1     John S. Grundy  1    
1 Arena Pharmaceuticals, Inc., San Diego, United States

Session
IBD (Posters)

Conference
UEG Week Virtual 2021

Citation
United European Gastroenterology Journal 2021; 9 (Supplement 8)


Login to access library content

Login

Do you need help setting up your myUEG account?
Contact us at [email protected]

New to myUEG?

Create myUEG account

Social Sharing